Mabion S.A.
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Contract Manufacturing Organization
Mabion S.A. is a Polish biopharmaceutical biologics partner providing comprehensive drug development and biomanufacturing services to pharmaceutical and biotech companies worldwide. The company supports clinical and commercial manufacturing of recombinant protein therapeutics, offering process and analytical development, GMP Drug Substance production from small scale up to 4 x 2,000 L single-use bioreactors, GMP Drug Product manufacturing on a state-of-the-art filling line, and a broad range of analytical and QC testing services. These capabilities are supported by strong quality assurance and regulatory affairs expertise. Mabion also contributed to the global fight against COVID-19 through a major agreement with Novavax Inc. for commercial production of the antigen for its COVID-19 vaccine. Mabion aims to become a key global partner in contract drug development and manufacturing. For more information about the Company, please visit www.mabion.eu.
Company HQ City:
Konstantynow Lodzki
Company HQ State:
Lodzkie
Company HQ Country:
Poland
Year Founded:
2007
Lead Product in Development:
MabionCD20 and ADC-related development programs
CEO
CEO - Gregor Kawaletz
Development Phase of Lead Product
Phase III
Exchange
Warsaw Stock Exchange (WSE)
Ticker
WSE: MAB or MAB:WSE.
When you expect your next catalyst update?
September 2026
What is your next catalyst (value inflection) update?
Mabion’s next value inflection update is expected to come from the execution of its 2026–2030 growth strategy, including the expansion into high-value biologics, ADC-related collaborations and the reactivation of MabionCD20 in new orphan disease indications. Key potential catalysts include further progress in the collaboration with Oddifact on MabionCD20, advancement of ADC-related partnerships with WPD Pharmaceuticals and KriSan Biotech, and conversion of ongoing strategic discussions into definitive agreements or new CDMO/co-development projects. These milestones would support Mabion’s positioning as a flexible European biologics partner focused on biosimilars, ADCs and complex biologics manufacturing.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}